Allogene Therapeutics, Inc.
ALLO evidence brief
What we can confirm
- BioSniper Score:
- 5.1 / 10
- Market Cap:
- $642.6M
- Lead Asset:
- ALLO-647 (Phase 1)
What it means
What to watch
Prepared research question
What matters most for ALLO—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · ALLO
Allogene Therapeutics is a clinical-stage biotechnology company developing allogeneic (off-the-shelf) CAR T cell therapies for cancer and autoimmune disease, with its most advanced program, cema-cel, in a pivotal Phase 2 trial for large B-cell lymphoma.
Key risk: Cash runway limited
BioSniper Score
Based on 4 of 6 signals
Market Cap
$642.6M
Cash Runway
—
Lead Asset
ALLO-647 (Phase 1)
Next Catalyst
—
Financial data as of Jun 30, 2026.
Tracking 1 pipeline candidate · 8 clinical trials for Allogene Therapeutics, Inc..
Allogene Therapeutics is a clinical-stage biotechnology company developing allogeneic (off-the-shelf) CAR T cell therapies for cancer and autoimmune disease, with its most advanced program, cema-cel, in a pivotal Phase 2 trial for large B-cell lymphoma.
- Cash & equivalents of $38.6M as of 2026-06-30 [sec].
- Total revenue of $4.6M and net loss of -$42.7M for the six months ended 2026-06-30 [sec].
- Pivotal Phase 2 ALPHA3 trial of cema-cel (first-line consolidation for large B-cell lymphoma) is enrolling at over 80 sites across the U.S., Canada, South Korea, and Australia as of 2026-08-12 [sec_mda].
- ALLO-316 (targeting CD70) showed a 31% confirmed response rate in advanced/metastatic RCC patients with CD70 TPS ≥50% in updated Phase 1 TRAVERSE data presented at ASCO 2025 [sec].
- Shareholders' equity of $436.2M as of 2026-06-30 [sec].
What works
- Cema-cel has received FDA designations and the company regained full development and commercial control in the U.S., EU, and UK, with EUR 20 million returned from escrow [sec].
- The ALPHA3 trial site activation target was accelerated by six months, with approximately 100 sites expected by year-end 2026, indicating strong investigator interest [news].
- ALLO-316 has advanced regulatory-path planning with the FDA for a potential pivotal/registration trial, supported by a 31% confirmed response rate in a high-CD70-expressing subgroup [sec].
What to weigh
- The company reported a net loss of -$42.7M for the six months ended 2026-06-30, with cash & equivalents of only $38.6M, indicating a high cash burn rate [sec].
- The next update for the pivotal ALPHA3 trial is not expected until mid-2027, with enrollment completion anticipated by year-end 2027, creating a long period without major catalysts [news].
- Allogene faces intense competition in both the LBCL space (16 competitors including Roche and Merck) and the RCC space (105 competitors) [pipeline].
- Forward-looking statements in SEC filings caution that clinical trial timelines and outcomes are inherently uncertain and subject to risks [sec].
From the filings
Quoted directly from source documents.
Cema-cel pivotal Phase 2 ALPHA3 trial enrollment status
“The study is currently enrolling at over 80 sites across the United States, Canada, South Korea and Australia.”
SEC MD&A · August 12, 2026
ALLO-316 response rate in RCC
“a 31% confirmed response rate in patients with CD70 TPS ≥50%”
SEC filings · April 30, 2026
Next ALPHA3 update timing
“Next Update Anticipated in Mid-2027, with Trial Enrollment Expected to Be Completed by Year-End 2027”
News · August 12, 2026
Risks & what to watch (4)›
Key risks
- Cash runway limited — Cash & equivalents of $38.6M as of 2026-06-30 against a net loss of -$42.7M in six months suggests less than one year of runway without additional financing [sec].
- Long wait for pivotal data — Next ALPHA3 update not until mid-2027; enrollment completion expected by year-end 2027, leaving a long period without major catalysts [news].
- Intense competitive landscape — Cema-cel faces 16 competitors in LBCL (including Phase 3 programs from Roche and Merck) and ALLO-316 faces 105 competitors in RCC [pipeline].
- Inherent clinical trial uncertainty — SEC filings caution that forward-looking statements about trial success, timing, and regulatory approval involve risks and uncertainties [sec].
What to watch
- Cash runway and any new financing or partnership announcements given the $38.6M cash position as of 2026-06-30 [sec].
- ALPHA3 trial enrollment progress toward the ~100-site target by year-end 2026 and the mid-2027 data update [news].
- FDA alignment discussions for ALLO-316 pivotal trial design and any potential strategic partnership for RCC [sec].
- Regulatory developments for cema-cel in the EU and UK following the return of EUR 20 million from escrow [sec].
Sources: News · Pipeline · SEC filings · SEC MD&A · Generated October 4, 2026 · How we verify sources →
Run Allogene Therapeutics, Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Allogene Therapeutics, Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 4 of 6 signals · derived from public data
Cash runway data unavailable
D/E 0.26 · 0% dilution
Lead: Phase 1
1 candidate
No upcoming catalysts tracked
0 buys · 2 sells (180d)
Pipeline
Regulatory
Financials
Short Interest
as of May 20, 2026- % of float
- 11.8%
- Days to cover
- 2.4
- Shares short
- 36,856,587
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
ALLO short interestGovernance
Frequently asked questions
What is the AI investment thesis for Allogene Therapeutics, Inc.?
Allogene Therapeutics is a clinical-stage biotechnology company developing allogeneic (off-the-shelf) CAR T cell therapies for cancer and autoimmune disease, with its most advanced program, cema-cel, in a pivotal Phase 2 trial for large B-cell lymphoma.
What is Allogene Therapeutics, Inc.'s lead drug candidate?
Allogene Therapeutics, Inc.'s most advanced tracked candidate is ALLO-647 (Phase 1) for Relapsed/Refractory Large B Cell Lymphoma; Advanced/Metastatic Clear Cell Renal Cell Carcinoma; Relapsed or Refractory Large B Cell Lymphoma, Relapsed or Refractory Chronic Lymphocytic Leukemia, Relapsed or Refractory Small Lymphocytic Lymphoma.
Who is the CEO of Allogene Therapeutics, Inc.?
Dr. Zachary J. Roberts M.D., Ph.D. is the chief executive officer of Allogene Therapeutics, Inc. (ALLO).
Where is Allogene Therapeutics, Inc. headquartered?
Allogene Therapeutics, Inc. (ALLO) is headquartered in South San Francisco, CA, United States.
What therapeutic areas does Allogene Therapeutics, Inc. focus on?
Allogene Therapeutics, Inc. develops therapies across Oncology, Gene Therapy, Immunology, Nephrology.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.